Rossari Biotech Expands Capacity at Unitop and Tristar Subsidiaries

Rossari Biotech Limited has approved significant capacity expansions at its subsidiaries, Unitop Chemicals Private Limited and Tristar Intermediates Private Limited, to meet growing market demand and enhance operational efficiency.

Unitop Chemicals Expansion

Unitop Chemicals will increase its capacity by 18,500 MTPA in a phased manner, expected to be completed by the 4th Quarter of FY 2025-26. The expansion, with an investment of ₹77 crore, will be funded through a mix of internal accruals and debt. This initiative aims to accommodate new product lines and strengthen the company’s competitive edge in both domestic and export markets.

Tristar Intermediates Expansion

Tristar Intermediates will add 3,600 MTPA to its existing capacity of 15,000 MTPA, which is currently operating at 90% utilization. The expansion, costing ₹20 crore, will also be financed through internal accruals and debt. The project includes upgrading existing equipment with modern technology to improve energy efficiency, product consistency, and process safety, while reducing long-term maintenance costs.

Strategic Growth Initiatives

These expansions are part of Rossari Biotech’s broader strategy to strengthen its growth capabilities. The company has announced a total capital expenditure of ₹192 crore for capacity expansions across Rossari and its subsidiaries, aiming to support growth across key chemistries, enhance supply reliability, and improve operational efficiency. Commissioning of these projects is expected by Q2 FY26.